Degradation of the cartilage proteoglycan, aggrecan, is an essential aspect of normal growth and development, and of joint pathology. The roles of different proteolytic enzymes in this process can be determined from the sites of cleavage in the aggrecan core protein, which generates novel termini (neoepitopes). Antibodies specific for the different neoepitopes generated by such cleavage events provide powerful tools with which to analyse these processes. The same approach can be used to differentiate the processed, active forms of proteases from their inactive pro-forms. Since the proteolytic processing of these enzymes requires the removal of the inhibitory pro-region, it also results in the generation of N-terminal neoepitopes. Using the newborn rat long bone as a model system, it was shown that the active form of ADAMTS-4 [ADAM (a disintegrin and metalloproteinase) with thrombospondin motifs-4], but not ADAMTS-5, co-localizes with the aggrecan cleavage neoepitopes known to be produced by this metalloproteinase. Thus, in long bone growth, aggrecan turnover seems to be dependent on ADAMTS-4 activity. To demonstrate the molecular basis of the specificity of anti-neoepitope antibodies, the Fv region of a monoclonal antibody specific for a neoepitope generated by the ADAMTS-4-mediated cleavage of aggrecan has been modelled and the binding of the peptide epitope simulated. In the docked structure, the N-terminus of the peptide antigen is clearly buried in the binding-site cavity. The absence of an open cleft makes it impossible for the intact substrate to pass through the binding site, providing a rationale for the specificity of this class of antibodies.
Introduction
Articular cartilage turnover is a critical feature of normal growth and development, and of degenerative diseases such as arthritis. Cartilage is a biocomposite material, and in simple terms can be considered to consist of a type II collagen network into which an underhydrated mass of the large aggregating proteoglycan, aggrecan, is embedded, giving the tissue its shock-absorbing properties. This proteoglycan is present in multimolecular complexes of 50 to 100 aggrecan molecules non-covalently bound through a specialized domain (G1) to a central hyaluronate filament, these interactions being stabilized by a small glycoprotein termed link protein ( Figure 1a ) [1] . While the turnover of cartilage collagen appears to be dependent on the action of the true collagenases (and perhaps cathepsin K), aggrecan is a substrate for most proteases [2] . However, analysis of natural aggrecan cleavage products indicates that two protease families mediate most of its degradation in vivo. Of particular importance is cleavage in the region close to the point of attachment of the aggrecan molecule to the hyaluronate filament. The region termed the interglobular domain (Figure 1b ) is particularly susceptible to proteolysis, and cleavage of the aggrecan core protein at sites along this domain allows the release of the glycosaminoglycan-containing portion of the molecule from the cartilage matrix, while leaving the globular region still associated with hyaluronate in the tissue. Matrix metalloproteinases (MMPs) such as stromelysin (MMP-3) have been shown to cleave aggrecan in this region at a specific site (Figure 1b ) [3] , and MMP-3-dependent cleavage products have been found in cartilage [4] . In addition, a second cleavage within the interglobular domain is found in both normal and diseased cartilage [5, 6] . This is produced by three members of a novel family of metalloproteinases that have the unusual specificity of cleavage following glutamic acid residues. The activities, termed aggrecanases, are due to the action of ADAMTS-4 [ADAM (a disintegrin and metalloproteinase) with thrombospondin motifs-4] [7] , ADAMTS-5 [8] and possibly ADAMTS-1 [9] (Figure 1c ). These multidomain proteases are closely related to the ADAM family [10] , but in addition contain a variable number of thrombospondin type 1 motifs that have been shown to assist in substrate binding (Figure 1c ) [11] . As with the ADAM family of proteases, the pro-forms of the ADAMTS are activated, prior to secretion, by furin (or furin-like enzymes) [12] . Our understanding of the cleavage of aggrecan in health and disease has been facilitated by the development of anti-peptide antibodies that are specific for the new termini generated following protease-mediated cleavage events [13] , but are unreactive with the intact substrate. These are commonly referred to as anti-neoepitope antibodies. Such reagents allow detection of the aggrecan neoepitopes …NITEGE and ARGSV… generated by ADAMTS-4 and ADAMTS-5 in vivo. The monoclonal antibody BC3 [14] produced against the ARGSV… epitope played a critical role in the characterization of these enzymes. In addition to mediating protein destruction, proteolysis is also an important aspect of biosynthesis, for example in the activation of the pro-form of ADAMTS-4 by the action of furin. Such processing steps also generate neoepitopes. As shown below, antibodies generated against peptides representing the new N-terminus of the ADAMTS family can be used to correlate the presence of active forms of these enzymes with the products of their activity.
Co-localization of aggrecan cleavage products and active enzyme
During long bone development, a cartilage model is replaced by bone, involving extensive turnover of the cartilage matrix. In order to allow for growth of the animal, the ends of the bone (the epiphyses) are remodelled separately. The cartilage primordium is invaded by blood vessels, and marrow spaces are established in the middle of the bone, resulting in the establishment of two zones of cartilage, termed growth plates. Chondroproliferation in these regions allows for elongation of the bone as the animal matures. In addition, a secondary centre of ossification is established in the epiphyses, allowing for growth in the end regions of the bone. At the cartilage/bone-marrow interface, rapid turnover of aggrecan occurs (Figure 2a) , making this tissue a very good system in which to study the role of specific proteases in the degradation of this proteoglycan. Using the proximal tibia of 21-day-old rat pups as a model system, a decrease in metachromasia (purple colour) in Toluidine Blue-stained sections, indicative of proteoglycan loss, is seen at the junction between the cartilage of the growth plate and the bone marrow space of a newly developed ossification centre (Figures 2b and 2c, arrows) . As shown previously [15] , the aggrecanase-generated neoepitope …NITEGE, representing the G1-containing product of aggrecanase cleavage, is immunolocalized at this site, as indicated by the brown reaction product shown in Figures 2(e) and 2(h).
Both ADAMTS-4 and ADAMTS-5 have been implicated in the turnover of aggrecan in cartilage. In order to evaluate the involvement of these enzymes in aggrecan turnover in the secondary centre of ossification, antibodies were prepared against the N-terminal neoepitopes generated following furin-mediated cleavage of the ADAMTS-4 and -5 proenzymes, and their specificity demonstrated using the recombinant proteases. While no reactivity was observed for ADAMTS-5, staining for active ADAMTS-4 was found to co-localize with that of the aggrecanase-generated G1 product (Figures 2f and 2i) , clearly indicating a cause-and-effect mechanism for the cleavage of aggrecan in this region.
Modelling of the Fv region of BC3 and peptide docking
Anti-neoepitope antibodies have been prepared using both mouse monoclonal and rabbit polyclonal approaches. A major advantage of the monoclonal method is that molecular details of the specific immunoglobulin can be determined. The antigen-binding unit (the Fv region) can be cloned, expressed as a recombinant protein and subjected to protein engineering methods to modify specificity. Such approaches depend on knowledge of the three-dimensional structure of the Fv region, preferably as a complex with the corresponding antigen. In the absence of an X-ray crystal structure, molecular modelling can provide this information, since the three-dimensional framework of the immunoglobulin fold is extremely well conserved and a large database of known structures is available. We have used this approach to investigate the molecular basis for the specificity of anti-neoepitope antibodies. Although good monoclonal antibodies have not been successfully prepared against the …NITEGE epitope, the monoclonal antibody BC3 was prepared against the N-terminal epitope (ARGSV…) generated at this cleavage site (Figure 1b) . It has been an extremely valuable reagent in the study of cartilage degradation. It was thus selected for detailed investigation of the molecular basis underlying its specificity.
Using appropriate degenerate primers, the variable regions of the light and heavy chains of the mouse monoclonal antibody BC3 were amplified by PCR using as a template cDNA reverse-transcribed from RNA prepared from the hybridoma cells. The derived amino acid sequences were used as the basis for homology modelling of the Fv three-dimensional structure using the program AbGen [16] , and the resulting structure was energy minimized using the program Discover (InsightII; MSI). When viewed as an accessible surface, the Fv region of the BC3 antibody model shows a closed-in deep pocket rather than a channel, suggesting that a terminal epitope, but not the uncleaved substrate, could fit into the binding site. In addition, the negative electrostatic character of the binding site would be expected to accommodate the N-terminal amino group of the peptide and the positive side chain of the arginine, the second residue of the neoepitope (Figure 3a) .
The peptide epitope Ala-Arg-Gly-Ser-Val-amide was docked into the antigen-binding site of the BC3 Fv region using Autodock3 [17] . This program allows for the flexibility of the ligand side chains, and yields different putative conformations of the bound peptide and corresponding estimated dissociation constants. Several clusters of putative binding conformations were obtained; however, those with the highest affinity (K i values in the low nanomolar range) showed similar conformations, as illustrated in Figure 3(b) . As predicted, the Nterminus of the peptide is buried deep in the binding site and the arginine side chain is well accepted. The remainder of the peptide then winds through and out of the binding site, as would be the case for the true aggrecan cleavage product.
These results show that insights into the binding of anti-neoepitope antibodies to their antigen can be obtained by molecular modelling approaches. Through protein engineering techniques, the affinity of these antibodies can be increased as is required for their use in immunoassays. In addition, since it has been difficult to produce antibodies specific for some neoepitopes, if may be possible to adapt the established frameworks to generate the required specificities. 
